Quest Diagnostics Hits New 52-Week High of $216.86, Surges 52.7%

Quest Diagnostics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 216.86 on July 1, 2026. This achievement underscores the company's strong performance over the past year, with a remarkable increase of 52.7%, significantly outpacing the S&P 500's growth of 20.74% during the same period. As a mid-cap company with a market capitalization of USD 31,451 million, Quest Diagnostics operates within the miscellaneous industry. The stock currently has a price-to-earnings (P/E) ratio of 28.00, reflecting its valuation in the market. Additionally, the company boasts a robust dividend yield of 29.40%, which may appeal to income-focused investors. Financially, Quest Diagnostics maintains a debt-to-equity ratio of 0.75, indicating a balanced approach to leveraging. The return on equity stands at 15.54%, showcasing the company's efficiency in generating profits from shareholders' equity. With a price-to-book ratio of 4.39, the stock's valuation remains a point of interest as it continues to perform well in the market.